• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Philip Morris International Inc

    2/13/23 3:54:33 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email
    SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. _ )*

                

    Philip Morris International Inc.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    718172109


    (CUSIP Number)

    December 30, 2022


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 718172109

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Capital International Investors
    95-1411037
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 102,617,417
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 103,019,220
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    103,019,220 Beneficial ownership disclaimed pursuant to Rule 13d-4
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.6%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Philip Morris International Inc.
    (b) Address of Issuer's Principal Executive Offices
    677 Washington Boulevard, Suite 1100, Stamford, CT 06901
    Item 2.
    (a) Name of Person Filing
    Capital International Investors
    (b) Address of Principal Business Office or, if None, Residence
    333 South Hope Street, 55th Fl, Los Angeles, CA 90071
    (c) Citizenship
    N/A
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    718172109
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    103,019,220 **
    (b) Percent of Class:
    6.6%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 102,617,417
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 103,019,220
    (iv) shared power to dispose or to direct the disposition of 0
    **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 103,019,220 shares or 6.6% of the 1,550,202,305 shares believed to be outstanding.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Capital International Investors
    By: /s/ Jae Won Chung
    Date: February 14, 2023
    Name: Jae Won Chung
    Title: Vice President and Associate Counsel, Fund Business Management Group, Capital Research and Management Company

    Get the next $PM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    7/9/2025$220.00Buy
    Jefferies
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    1/23/2024$105.00 → $86.50Buy → Sell
    UBS
    More analyst ratings

    $PM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Philip Morris International Inc

      10-Q - Philip Morris International Inc. (0001413329) (Filer)

      7/25/25 8:11:01 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Philip Morris International Inc. (0001413329) (Filer)

      7/22/25 7:03:11 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 11-K filed by Philip Morris International Inc

      11-K - Philip Morris International Inc. (0001413329) (Filer)

      6/27/25 3:14:58 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NYSE Content Advisory: Pre-market update + S&P 500 coming off record close

      NEW YORK, July 22, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on July 22nd Equities are little changed Tuesday morning after the S&P 500 hit a new record on Monday. The large-cap index's gains come as earnings season ramps up.Prior to market open, NYSE-listed firms including Coca-Cola (NYSE:KO), General Motors (NYSE:GM), and Philip Morris (NYSE:PM) will report their Q2 earnings ahead of the White House's reciprocal tariff rollout on August 1st.Inve

      7/22/25 8:55:00 AM ET
      $CIB
      $GM
      $ICE
      $KO
      Commercial Banks
      Finance
      Auto Manufacturing
      Consumer Discretionary
    • Philip Morris International Reports 2025 Second Quarter & First Six-Months Results and Raises Full-Year Guidance; Second Quarter Reported Diluted EPS Grew 26.6% to $1.95, Adjusted Diluted EPS Grew 20.1% to $1.91, and by 18.9% excluding currency

      Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 second quarter results.1 "Our business delivered very strong results in the second quarter, with record net revenues and exceptional growth in operating income and adjusted diluted EPS," said Jacek Olczak, Chief Executive Officer. "These results reflect excellent momentum in our multicategory smoke-free business, with a reacceleration of IQOS adjusted in-market sales growth and ZYN U.S. offtake growth, coupled with combustibles resilience. Given our strong year-to-date performance, we are raising our full-year guidance." _____________________________ 1 Explanation of PMI's use of non-GAAP me

      7/22/25 6:59:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International to Host Webcast of 2025 Second-Quarter and First-Half Results

      Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast at www.pmi.com/2025Q2earnings on Tuesday, July 22, 2025, at 9:00 a.m. ET, to discuss its 2025 second-quarter and first-half results, which will be issued at approximately 7:00 a.m. ET the same day. The webcast will be hosted by Emmanuel Babeau, Chief Financial Officer, and will include discussion of PMI's financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. The webcast recording and the slides and script will be avai

      7/15/25 8:59:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies resumed coverage on Philip Morris International with a new price target

      Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

      7/9/25 8:31:10 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Needham initiated coverage on Philip Morris International with a new price target

      Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

      5/22/25 8:27:06 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International upgraded by UBS with a new price target

      UBS upgraded Philip Morris International from Sell to Neutral and set a new price target of $170.00

      4/25/25 8:25:28 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Trumpaitis Mindaugas claimed ownership of 73,002 shares (SEC Form 3)

      3 - Philip Morris International Inc. (0001413329) (Issuer)

      6/9/25 3:34:30 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Temperley Dessislava was granted 1,002 shares, increasing direct ownership by 15% to 7,756 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      5/9/25 4:54:43 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Bough Bonin was granted 1,002 shares, increasing direct ownership by 11% to 9,834 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      5/9/25 4:54:34 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    See more
    • Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

      Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

      9/17/24 9:11:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Names New External Affairs Leader

      Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

      3/26/24 5:48:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International's U.S. Business Champions Female Economic Growth in Connecticut with Record-Setting $5 Million Investment Through New Partnership with Women's Business Development Council

      In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002

      3/4/24 6:48:00 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Financials

    Live finance-specific insights

    See more
    • Philip Morris International Reports 2025 Second Quarter & First Six-Months Results and Raises Full-Year Guidance; Second Quarter Reported Diluted EPS Grew 26.6% to $1.95, Adjusted Diluted EPS Grew 20.1% to $1.91, and by 18.9% excluding currency

      Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 second quarter results.1 "Our business delivered very strong results in the second quarter, with record net revenues and exceptional growth in operating income and adjusted diluted EPS," said Jacek Olczak, Chief Executive Officer. "These results reflect excellent momentum in our multicategory smoke-free business, with a reacceleration of IQOS adjusted in-market sales growth and ZYN U.S. offtake growth, coupled with combustibles resilience. Given our strong year-to-date performance, we are raising our full-year guidance." _____________________________ 1 Explanation of PMI's use of non-GAAP me

      7/22/25 6:59:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Declares Regular Quarterly Dividend of $1.35 Per Share

      Regulatory News: The Board of Directors of Philip Morris International Inc. (PMI) (NYSE:PM) today declared a regular quarterly dividend of $1.35 per common share, payable on July 15, 2025, to shareholders of record as of June 27, 2025. The ex-dividend date is June 27, 2025. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primar

      6/13/25 5:45:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Participates in dbAccess Global Consumer Conference

      Reaffirms 2025 Full-Year Forecast for Reported Diluted EPS of $7.01 to $7.14 and Adjusted Diluted EPS of $7.36 to $7.49, Representing Growth of 12% to 14%, 10.5% to 12.5% Excluding Currency Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2025 dbAccess Global Consumer Conference in Paris. The event will be webcast live in listen-only mode, beginning at approximately 11:15 a.m. CEST (5:15 a.m. EST), at www.pmi.com/2025dbaccess and on the PMI Investor Relations Mobile Application (www.pmi.com/irapp). An archived copy of the webcast will be available for approximately one year. 2025 Full-Ye

      6/3/25 1:30:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/9/24 6:21:26 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/9/24 6:05:54 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      1/29/24 3:26:29 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care